Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 705564 (Double-blind, Randomised, Placebo-controlled, Parallel-group Design) and Evaluation of Midazolam Interaction (Nested, Open, Fixed-sequence, Intra-individual Comparison) in Healthy Male Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs BI 705564 (Primary) ; Midazolam
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Dec 2018 Planned End Date changed from 26 Nov 2018 to 15 Feb 2019.
- 13 Dec 2018 Planned primary completion date changed from 26 Nov 2018 to 15 Feb 2019.
- 01 Nov 2018 Status changed from recruiting to active, no longer recruiting.